Can TRT Contribute to Small Bowel Obstruction?

Testosterone replacement therapy can raise red blood cell production. Rare reports also link excessive androgen exposure with adult intussusception. This occurs when one bowel segment telescopes into another and sometimes creates a mechanical obstruction.

However, therapeutic TRT and anabolic steroid misuse are not equivalent. Most cases involved bodybuilding-level doses, stacked compounds, or incomplete monitoring. The literature does not establish small bowel obstruction as a recognized complication of properly dosed TRT.

Intussusception and Small Bowel Obstruction Are Not Identical

A small bowel obstruction blocks intestinal contents. Adhesions after abdominal surgery remain the leading cause. Hernias, tumors, inflammatory disease, and volvulus provide other explanations.

Intussusception represents a much less common mechanism. It may obstruct the bowel, impair blood flow, or resolve spontaneously. Several widely cited androgen cases documented intussusception without obstruction. Adults still require evaluation for a tumor, polyp, inflammation, or another structural lead point.⁹

What Testosterone Clearly Does to Red Blood Cells

Testosterone stimulates red blood cell production in a dose-dependent manner. It changes erythropoietin signaling and lowers hepcidin, making more iron available for hemoglobin production.

The result can be secondary erythrocytosis, meaning an elevated hemoglobin or hematocrit. This differs from polycythemia vera, a primary bone marrow disorder. Dehydration can also raise hematocrit temporarily by reducing plasma volume.

Higher doses, injectable formulations, older age, sleep apnea, smoking, and chronic hypoxia can amplify the rise. A 2025 systematic review reported thromboembolic events in up to 2.7% of some testosterone cohorts. However, it could not prove that erythrocytosis caused them.⁶

The broader evidence remains mixed. A trial meta-analysis found no significant increase in venous thromboembolism, but its confidence intervals remained wide.⁷ TRAVERSE found no increase in major cardiovascular events. Still, pulmonary embolism occurred in 0.9% with testosterone and 0.5% with placebo.⁸

The Proposed “Thick Blood” Cascade

The phrase “thick blood” offers a useful shortcut, but it can imply more certainty than the evidence supports. Researchers have proposed the following sequence:

Step	Strength of Evidence	Clinical Meaning
Excess androgen exposure increases erythropoiesis	Established	Hemoglobin and hematocrit can rise, especially with higher doses
Rising hematocrit increases blood viscosity	Established physiology	Flow may become less efficient, particularly with dehydration or hypoxia
Mesenteric thrombosis or impaired flow injures bowel	Documented rarely	Portal or mesenteric clots can cause congestion, ischemia, and swelling
Swollen bowel forms a lead point	Plausible but unproven	Case authors proposed this mechanism; most did not directly show microthrombi
Intussusception causes obstruction	Established when persistent	Short transient intussusceptions may cause no obstruction at all

The complete cascade remains a coherent hypothesis, not a demonstrated pathway. Dehydration, hypoxia, other drugs, and individual clotting risk may shape the outcome.

What the Published Cases Actually Show

• Case 1 — Extreme Stacked Androgen Exposure: A 34-year-old bodybuilder used 1,500 mg weekly of combined testosterone and nandrolone, later reducing to 500 mg. His hematocrit measured 51.2%. CT showed two small bowel intussusceptions without obstruction. Hydration resolved them.¹
• Case 2 — Chronic Steroids and Transient Intussusception: A 36-year-old anabolic steroid user developed polycythemia and jejunal intussusception. Laparoscopy found bowel thickening but no continuing intussusception or obstruction. Histology was normal.²
• Case 3 — Testosterone With Post-Cycle Drugs: A 23-year-old man used testosterone at 500 mg weekly, then tamoxifen and clomiphene. He developed colonic, not small bowel, intussusception. Surgery showed mucosal necrosis and vascular congestion without cancer. His blood count remained upper-normal. Tamoxifen also carries thrombotic risk, so the report cannot isolate testosterone.³
• Case 4 — Recurrent Episodes Before Disclosure: A 28-year-old man developed recurrent small bowel intussusception and obstructive symptoms. No tumor emerged. He later disclosed regular anabolic steroid use, while hematocrit reached 51%. Recurrence strengthened suspicion without proving the ischemic mechanism._⁴
• Case 5 — Mesenteric Thrombosis During TRT: A 59-year-old man receiving intramuscular TRT developed portal and mesenteric venous thrombosis. His hemoglobin measured 18.9 g/dL. Bowel ischemia and obstruction followed. Without his dose or testosterone level, the report cannot confirm physiologic treatment.⁵

These reports create a signal, but they neither establish incidence nor prove causation.

Therapeutic TRT and Anabolic Steroid Use Are Different

Feature	Individualized TRT	Anabolic Steroid Misuse
Primary goal	Restore a documented deficiency	Produce supraphysiologic muscle or performance effects
Testosterone target	Physiologic, usually mid-normal	Often far above the normal range
Typical approach	One selected formulation with dose adjustment	High doses, stacking, cycling, or post-cycle drugs
Monitoring	Testosterone level, CBC, symptoms, and related risks	Often inconsistent or absent
Bowel evidence	Isolated vascular case reports	Small cluster of intussusception reports

Dose alone does not define safe care. Serum testosterone, hematocrit trends, symptoms, and vascular context matter more.

Monitoring Is the Main Preventive Strategy

The Endocrine Society recommends checking hematocrit before TRT, after three to six months, and then annually. Rising values warrant closer testing.¹⁰

A hematocrit above 54% calls for holding treatment, evaluating hypoxia and sleep apnea, and later restarting at a lower dose. This represents an intervention ceiling, not an ideal target.

A thoughtful response may include:

• Reducing the testosterone dose or changing the formulation
• Confirming the testosterone level at the correct point in the dosing cycle
• Treating sleep apnea, hypoxia, smoking, or dehydration
• Reviewing prior clots, inherited thrombophilia, and interacting medications
• Considering phlebotomy selectively rather than using repeated blood donation to support excessive dosing

Phlebotomy lowers hematocrit but can deplete iron. Evidence for its long-term safety in testosterone-induced erythrocytosis remains limited. Dose correction remains central.¹¹

When Abdominal Symptoms Require Immediate Evaluation

High hematocrit does not diagnose bowel ischemia. A normal blood count does not exclude it.

Seek immediate evaluation for severe or escalating abdominal pain, repeated vomiting, marked distention, or inability to pass stool or gas. Bloody stool, faintness, fever, or pain that seems disproportionate to the examination adds further urgency. CT imaging usually determines whether obstruction, intussusception, or vascular compromise is present.

Why Holistic, Individualized Care Matters

TRT safety depends on more than one testosterone value. Hematocrit, sleep apnea, oxygenation, smoking, cardiovascular health, hydration, and medication combinations interact. Balanced care recognizes the signal without turning rare reports into a common danger.

Frequently Asked Questions

1. Can TRT cause a small bowel obstruction? Current evidence does not establish small bowel obstruction as a recognized complication of properly prescribed and monitored TRT. Rare reports describe intussusception or abdominal venous thrombosis during testosterone exposure. Most intussusception cases involved supraphysiologic anabolic-steroid use or other confounding factors.
2. What evidence links testosterone with intussusception? Several case reports describe adult intussusception among men using high-dose anabolic steroids. Some patients had elevated hematocrit, but several episodes occurred without a true obstruction. Case reports can identify a possible signal but cannot prove causation or determine incidence.
3. How does testosterone raise hematocrit? Testosterone stimulates red blood cell production through several pathways. It affects erythropoietin signaling and lowers hepcidin, making more iron available for hemoglobin production. The effect is dose-dependent and can be greater with injectable formulations.
4. Can high hematocrit cause bowel obstruction? High hematocrit alone does not directly diagnose or prove a bowel obstruction. Increased viscosity may contribute to impaired blood flow or thrombosis in susceptible patients. The proposed progression from vascular injury to bowel swelling and intussusception remains unproven.
5. Is anabolic-steroid use the same as medically supervised TRT? No. Medical TRT aims to restore testosterone to a physiologic range using individualized dosing and laboratory monitoring. Anabolic-steroid misuse often involves much higher doses, multiple compounds, cycling, or post-cycle drugs.
6. What hematocrit level requires action during TRT? The Endocrine Society identifies a hematocrit above 54% as a threshold for temporarily stopping therapy and evaluating contributing conditions. A clinician may intervene earlier based on the patient’s trend, symptoms, and vascular risk.
7. How often should hematocrit be checked during TRT? The Endocrine Society recommends checking hematocrit before treatment and again after three to six months. Annual monitoring follows when results remain stable. Patients with rising values or additional risk factors may need more frequent testing.
8. Which abdominal symptoms require emergency care? Severe or worsening abdominal pain, repeated vomiting, marked bloating, or inability to pass stool or gas requires immediate evaluation. Bloody stool, fainting, fever, or unusually severe pain adds further urgency.

Takeaway

Rare reports suggest that excessive androgen exposure may contribute to adult intussusception and occasional bowel obstruction. The proposed bridge involves erythrocytosis, hyperviscosity, vascular injury, and bowel wall swelling. Yet several links remain hypothetical, and most cases involved anabolic steroid misuse rather than monitored TRT.

At our practice in Montgomery County, Maryland, and through virtual care, we manage TRT through individualized dosing and careful laboratory follow-up. We also evaluate sleep, oxygenation, metabolic health, and vascular risk. This integrated approach protects the benefits of testosterone while reducing avoidable complications.